Investment
Features
FeesSafety
Academy
More
Pluang+

Compare DexCom, Inc. (DXCM) vs Lamb Weston Holdings Inc (LW) Price & Performance

DexCom, Inc.Trade
Lamb Weston Holdings IncTrade

Price performance (Past 24H)

Key statistics

DexCom, Inc. vs Lamb Weston Holdings Inc — how do they compare? DexCom, Inc. trades at $84.03 (market cap $31.86B), while Lamb Weston Holdings Inc trades at $48.22 (market cap $6.81B). The key difference: DexCom, Inc. is far larger — about 4.7× Lamb Weston Holdings Inc's market cap, and Lamb Weston Holdings Inc pays a 3.07% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Lamb Weston Holdings Inc for 66 Days on average.

DXCMLW
Market Cap
$31.86B$6.81B
Volume
3,607,0704,638,686
Sector
HealthConsumer Staples
52-Week High
$92.34$66.57
52-Week Low
$54.84$38.48
Typical Hold Time
62 Days66 Days
Enterprise Value
$31.32B$10.61B
Dividend Yield
—3.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

DexCom, Inc.

DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.

The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.

Lamb Weston Holdings Inc

Lamb Weston (LW) trades at $48.09, up 0.38% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 14.17% ROE and trades at a P/E of 27.03. Recent news highlights cost savings exceeding $100 million and analyst anticipation for upcoming Q1 earnings. The consensus price target is $53.71, suggesting potential upside from current levels.

The outlook is cautiously optimistic, supported by earnings momentum and operational improvements, but risks include margin pressure from rising costs and a high debt load. Investor sentiment is mixed amid legal scrutiny and institutional selling, requiring careful monitoring of execution against guidance.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DXCM
100% Buy0% Sell
Avg holding period · 62 Days
LW

No sentiment data available yet.

Top news

Latest headlines on both assets

About DexCom, Inc.

Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.

Read more on DXCM →

About Lamb Weston Holdings Inc

Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.

Read more on LW →